Canada - français - Health Canada

dmvet inc - dextrose - solution - 50% - dextrose 50% - bétails; porcs; chevaux; mouton

Canada - français - Health Canada

dmvet inc - dextrose; gluconate de magnésium; gluconate de calcium; hypophosphite de calcium - solution - 15%; 5.8%; 20.55%; 1.37% - dextrose 15%; gluconate de magnésium 5.8%; gluconate de calcium 20.55%; hypophosphite de calcium 1.37% - bétails; porcs; chevaux; mouton

Canada - français - Health Canada

dmvet inc - chlorure de sodium - solution - 0.9g - chlorure de sodium 0.9g - bétails; porcs; chevaux; chats; mouton; chiens

Canada - français - Health Canada

dmvet inc - chlorure de sodium; lactate de sodium; chlorure de potassium; chlorure de calcium - solution - 6g; 3.1g; 0.3g; 0.2g - chlorure de sodium 6g; lactate de sodium 3.1g; chlorure de potassium 0.3g; chlorure de calcium 0.2g - bétails; porcs; chevaux; chats; mouton; chiens

Canada - français - Health Canada

dmvet inc - gluconate de calcium monohydraté - solution - 23.963% - gluconate de calcium monohydraté 23.963% - bétails; porcs; mouton

Canada - français - Health Canada

dmvet inc - eau stérile - liquide - 100% - eau stérile 100% - bétails; porcs; chèvres; chevaux; chats; mouton; chiens

Canada - français - Health Canada

dmvet inc - dextrose; sorbitol; lactate de sodium; chlorure de sodium; chlorure de potassium; chlorure de magnésium; chlorure de calcium - solution - 25.0mg; 25.0mg; 7.87mg; 4.8mg; 0.74mg; 0.42mg; 0.38mg - dextrose 25.0mg; sorbitol 25.0mg; lactate de sodium 7.87mg; chlorure de sodium 4.8mg; chlorure de potassium 0.74mg; chlorure de magnésium 0.42mg; chlorure de calcium 0.38mg - bétails; porcs; chevaux; mouton

Canada - français - Health Canada

dmvet inc - chlorure de sodium - solution - 7.2g - chlorure de sodium 7.2g - bétails

Union européenne - français - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - cellule précurseur leucémie lymphoblastique - lymphome - agents antinéoplasiques - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Union européenne - français - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - agents de modification des lipides - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.